News
RLAY
17.88
+2.70%
0.47
Most shorted stocks on Wall Street
Seeking Alpha · 6d ago
Weekly Report: what happened at RLAY last week (0928-1002)?
Weekly Report · 6d ago
Weekly Report: what happened at RLAY last week (0921-0925)?
Weekly Report · 09/28 09:49
Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset
TipRanks · 09/25 12:30
Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing
Seeking Alpha · 09/24 18:59
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX) and Relay Therapeutics (RLAY)
TipRanks · 09/22 17:00
Weekly Report: what happened at RLAY last week (0914-0918)?
Weekly Report · 09/21 09:49
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 09/17 13:45
Weekly Report: what happened at RLAY last week (0907-0911)?
Weekly Report · 09/14 09:52
Weekly Report: what happened at RLAY last week (0831-0904)?
Weekly Report · 09/07 09:48
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September
Barchart · 09/01 15:46
Weekly Report: what happened at RLAY last week (0824-0828)?
Weekly Report · 08/31 09:52
Major Investor Makes Dramatic Exit From Relay Therapeutics
TipRanks · 08/29 02:09
Weekly Report: what happened at RLAY last week (0817-0821)?
Weekly Report · 08/24 09:53
Relay Therapeutics Price Target Raised to $29.00/Share From $28.00 by HC Wainwright & Co.
Dow Jones · 08/20 11:52
Relay Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/20 11:52
HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $29
Benzinga · 08/20 11:42
Relay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
TipRanks · 08/20 10:10
The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci
NASDAQ · 08/18 07:43
Weekly Report: what happened at RLAY last week (0810-0814)?
Weekly Report · 08/17 09:53
More
Webull provides a variety of real-time RLAY stock news. You can receive the latest news about Relay Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RLAY
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.